Melanotan 2
FDA has identified it as an unapproved new drug (Manookian/Melanocorp Electronic Reading Room notice); never completed clinical development or received approval for any indication.
Melanotan 2 is a synthetic, cyclic, non-selective analogue of alpha-MSH that activates multiple melanocortin receptors: MC1R (driving melanogenesis, its intended research use) and MC3R/MC4R (implicate...
Sequence
Mechanism of Action
Melanotan 2 is a synthetic, cyclic, non-selective analogue of alpha-MSH that activates multiple melanocortin receptors: MC1R (driving melanogenesis, its intended research use) and MC3R/MC4R (implicated in off-target appetite and sexual-function effects observed in early pharmacology studies). Its lack of receptor selectivity relative to afamelanotide is understood to be why it was never advanced as an approved drug.